0001574094
false
0001574094
2023-08-17
2023-08-17
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): August 17, 2023
RENOVORX,
INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-40738 |
|
27-1448452 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
4546
El Camino Real, Suite B1 Los Altos, CA |
|
94022 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (650) 284-4433
Not
Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instructions A.2. below):
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, $0.0001 par value per share |
|
RNXT |
|
Nasdaq
Capital Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 |
Results
of Operations and Financial Condition. |
On
August 17, 2023, RenovoRx, Inc. (the “Company”) issued a press release announcing its financial results for the quarter
ended June 30, 2023. The full text of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
All
of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) of this Current Report on Form 8-K shall not be
deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as
shall be expressly set forth by specific reference in such a filing.
Item 9.01 |
Financial Statements
and Exhibits |
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
RENOVORX, INC. |
Date:
August 17, 2023 |
|
|
|
|
|
|
By: |
/s/ Shaun
R. Bagai |
|
Name: |
Shaun R. Bagai |
|
Title: |
Chief Executive Officer |
Exhibit
99.1
RenovoRx Reports Second Quarter 2023
Financial Results and Operational Highlights
Presented
positive Phase III TIGeR-PaC interim study results observing 8-month delay in cancer progression, concordant with 6-month overall survival
benefit and 65% reduction in adverse effects over standard of care.
Announced collaboration with
Imugene to explore delivery of oncolytic virus therapy using proprietary Trans-Arterial Micro-Perfusion (TAMP™) platform,
expanding use from targeting locally advanced disease to treating metastatic disease.
Los
Altos, CA, August 17, 2023 - RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a
clinical-stage biopharmaceutical company developing targeted combination therapies, today announced financial results for the second
quarter ended June 30, 2023.
“We
made strong progress this quarter and have continued momentum in our commitment
to transform the lives of patients by delivering innovative solutions to change the current paradigm of cancer care,” said Shaun
Bagai, CEO of RenovoRx. “This quarter marked significant milestones including positive interim data presented from our pivotal
Phase III TIGeR-PaC study, a strategic collaboration to potentially utilize immunotherapy to expand our platform to help metastatic patients,
and key additions to our leadership team, Board of Directors and Scientific Advisory Board. We
are also excited for the upcoming year, when we expect our secondary interim analysis data readout.”
Key
Business Highlights:
| ● | •
Presented positive Phase III data demonstrating RenovoGem delays cancer progression
by 8-months, while providing a 6-month overall survival benefit and 65% reduction
in adverse effects over standard of care in locally advanced pancreatic cancer
patients, at 2023 ESMO World Congress in Gastrointestinal Cancer and American Association
for Cancer Research Annual Meeting. |
| ● | Initiated
patient enrollment at the University of Texas Southwestern Medical Center for pivotal Phase III TIGeR-PaC clinical trial. |
| ● | •
Launched collaboration with Imugene Ltd (ASX: IMU) to explore a better way to deliver oncolytic
immunotherapy in difficult to access to tumors, such as metastatic pancreatic cancer, using
RenovoRx’s proprietary TAMP therapy platform. This collaboration potentially expands
the market for the TAMP platform beyond locally advanced to metastatic pancreatic cancer. |
| ● | Appointed
Margaret A. Tempero, M.D., Director, UCSF Pancreas Center and Leader of the UCSF Pancreas
Cancer Program, to the Company’s Scientific Advisory Board (SAB). |
| ● | Appointed
Robert J. Spiegel, MD to the Company’s Board of Directors. Dr.
Spiegel is former Chief Medical Officer of Schering-Plough ($41B merger with Merck MSD).
His experience includes involvement involved in more than 30 successful New Drug Application
(NDA) approvals by the FDA and the development and launch of multiple products with annual
sales exceeding $1B. |
| ● | Appointed
Leesa Gentry as Senior Vice President of Clinical Operations to lead RenovoRx’s
expansive clinical programs. Ms. Gentry is an industry expert in clinical trials management
with prior senior leadership experience at Evotec, PPD, Quintiles and Otsuka America Pharmaceutical. |
| ● | Closed
a registered direct offering and a concurrent private placement for aggregate gross proceeds of $5 million. |
Second
Quarter 2023 Financial Results:
| ● | Cash
Position: Cash and cash equivalents as of June 30, 2023, were $6.0 million. |
| ● | R&D
Expenses: Research and development expenses were $1.9 million for the quarter ended June
30, 2023, compared to $1.4 million for the quarter ended June 30, 2022. The increase was
primarily due to our ongoing Phase III clinical trial costs and an increase in employee and
related benefits costs. This increase was partially offset by a decrease in costs associated
with a secondary manufacturer. |
| ● | G&A
Expenses: General and administrative expenses were $1.4 million for the second quarter
ended June 30, 2023, compared to $1.2 million for the quarter ended June 30, 2022. This increase
was primarily due to higher employee and related benefits costs due to an increased in headcount.
This increase was partially offset by a decrease in professional and consulting fees compared
to the same period last year. |
| ● | Net
Loss: Net loss was $2.3 million for the quarter ended June 30, 2023, compared
to net loss of $2.6 million for the quarter ended June 30, 2022. |
| ● | Shares
Outstanding: Shares of common stock outstanding, as of June 30, 2023, were 10,693,080. |
About
RenovoRx, Inc.
RenovoRx
is a clinical-stage biopharmaceutical company developing targeted combination therapies for high unmet medical needs. The Company’s
proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to bypass traditional systemic delivery methods
and ensure precise therapeutic delivery to a target tissue, while minimizing a therapy’s systemic toxicities. RenovoRx’s
unique approach to drug-delivery offers the potential for increased treatment safety, tolerance, and wider therapeutic windows. The Company’s
lead product candidate, RenovoGem™ combines gemcitabine with the company’s patented delivery system and is regulated by FDA
under the IND 21 CFR 312 pathway. RenovoGem is currently in a Phase III clinical trial (TIGeR-PaC) for the treatment of locally advanced
pancreatic cancer, where it observed a 6-month median Overall Survival benefit, 8-month progression-free survival (PFS) and 65% reduction
in adverse events at its interim analysis. RenovoRx is committed to transforming the lives of patients by delivering innovative solutions
to change the current paradigm of cancer care. RenovoGem is currently under investigation for TAMP therapeutic delivery of gemcitabine
and has not been approved for commercial sale.
For
more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and Twitter.
Forward-Looking
Statements
This
press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of
the Securities Exchange Act of 1934, including but not limited to statements regarding our clinical trials and studies, including anticipated
timing, statements regarding the potential of RenovoCath®, RenovoGemTM or TAMPTM or regarding our
ongoing TIGeR-PaC Phase III clinical trial study in LAPC, statements regarding the potential for our product candidates to treat or provide
clinically meaningful outcomes for certain medical conditions or diseases, and our preliminary financial results, cash position and related
ability to continue as a going concern. Statements that are not purely historical are forward-looking statements. The forward-looking
statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature,
are inherently uncertain, outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These
may include estimates, projections and statements relating to our research and development plans, clinical trials, therapy platform,
business plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to
known and unknown risks and uncertainties that may cause actual results to differ materially from those expressed or implied by these
forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,”
“aims,” “anticipates,” “believes,” “forecasts,” “estimates,” “intends,”
and “potential,” or the negative of these terms or other comparable terminology regarding RenovoRx’s expectations strategy,
plans or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to
a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated
by such statements, including, among other things: the timing of the initiation, progress and potential results of our preclinical studies,
clinical trials and our research programs; the possibility that interim results may not be predictive of the outcome of our clinical
trial, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate, or the regulatory
authority may disagree with our interpretation of the data; research and clinical development plans and timelines, and the regulatory
process for our product candidates; future potential regulatory milestones for our product candidates, including those related to current
and planned clinical studies; our ability to use and expand our therapy platform to build a pipeline of product candidates; our ability
to advance product candidates into, and successfully complete, clinical trials; the timing or likelihood of regulatory filings and approvals;
our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our
clinical trials; the commercialization potential of our product candidates, if approved; our ability and the potential to successfully
manufacture and supply our product candidates for clinical trials and for commercial use, if approved; future strategic arrangements
and/or collaborations and the potential benefits of such arrangements; our estimates regarding expenses, future revenue, capital requirements
and needs for additional financing and our ability to obtain additional capital; the sufficiency of our existing cash and cash equivalents
to fund our future operating expenses and capital expenditure requirements; our ability to retain the continued service of our key personnel
and to identify, hire and retain additional qualified personnel; the implementation of our strategic plans for our business and product
candidates; the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform,
product candidates and research programs; our ability to contract with third-party suppliers and manufacturers and their ability to perform
adequately; the pricing, coverage and reimbursement of our product candidates, if approved; developments relating to our competitors
and our industry, including competing product candidates and therapies; negative impacts of the ongoing COVID-19 pandemic on our operations;
and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors”
in documents that we file from time to time with the Securities and Exchange Commission.
Forward-looking
statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking
statements to reflect subsequent events or circumstances, except as required by law.
RenovoRx,
Inc.
Selected
Condensed Balance Sheet Data
(Unaudited)
(in
thousands)
| |
June 30, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
Cash, cash equivalents and marketable securities | |
$ | 5,954 | | |
$ | 6,440 | |
Total assets | |
$ | 6,314 | | |
$ | 7,265 | |
| |
| | | |
| | |
Current liabilities | |
$ | 1,699 | | |
$ | 1,102 | |
Common warrant liability | |
| 3,427 | | |
| - | |
Total liabilities | |
$ | 5,126 | | |
$ | 1,102 | |
Total stockholders’ equity | |
$ | 1,188 | | |
$ | 6,163 | |
Total liabilities and stockholders’ equity | |
$ | 6,314 | | |
$ | 7,265 | |
RenovoRx,
Inc.
Condensed
Statements of Operations and Comprehensive Loss
(Unaudited)
(in
thousands, except share and per share amounts)
| |
Three Months Ended | | |
Six Months Ended | |
| |
June 30, | | |
June 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Research and development | |
$ | 1,925 | | |
$ | 1,390 | | |
$ | 3,263 | | |
$ | 2,679 | |
General and administrative | |
| 1,450 | | |
| 1,224 | | |
| 3,373 | | |
| 2,940 | |
Total operating expenses | |
| 3,375 | | |
| 2,614 | | |
| 6,636 | | |
| 5,619 | |
Loss from operations | |
| (3,375 | ) | |
| (2,614 | ) | |
| (6,636 | ) | |
| (5,619 | ) |
Other income/(expenses), net: | |
| | | |
| | | |
| | | |
| | |
Interest and dividend income | |
| 50 | | |
| 20 | | |
| 54 | | |
| 21 | |
Other income, net | |
| - | | |
| - | | |
| - | | |
| 1 | |
Change in fair value of common warrant liability | |
| 1,573 | | |
| - | | |
| 1,573 | | |
| - | |
Transaction costs
allocated to common warrant liability | |
| (575 | ) | |
| - | | |
| (575 | ) | |
| - | |
Total other income/(expenses), net | |
| 1,048 | | |
| 20 | | |
| 1,052 | | |
| 22 | |
Net loss | |
| (2,327 | ) | |
| (2,594 | ) | |
| (5,584 | ) | |
| (5,597 | ) |
Other comprehensive loss: | |
| | | |
| | | |
| | | |
| | |
Unrealized loss on marketable securities | |
| - | | |
| (4 | ) | |
| - | | |
| (4 | ) |
Comprehensive loss | |
$ | (2,327 | ) | |
$ | (2,598 | ) | |
$ | (5,584 | ) | |
$ | (5,601 | ) |
Net loss per share, basic and diluted | |
$ | (0.22 | ) | |
$ | (0.29 | ) | |
$ | (0.57 | ) | |
$ | (0.62 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted-average shares of common stock outstanding, basic and diluted | |
| 10,655,155 | | |
| 9,057,185 | | |
| 9,881,371 | | |
| 9,024,973 | |
Investor
Contact:
KCSA
Strategic Communications
Valter
Pinto or Jack Perkins
T:212-896-1254
renovorx@kcsa.com
Media
Contact:
Kimberly
Ha
KKH
Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
v3.23.2
Cover
|
Aug. 17, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Aug. 17, 2023
|
Entity File Number |
001-40738
|
Entity Registrant Name |
RENOVORX,
INC.
|
Entity Central Index Key |
0001574094
|
Entity Tax Identification Number |
27-1448452
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
4546
El Camino Real
|
Entity Address, Address Line Two |
Suite
|
Entity Address, City or Town |
Los Altos
|
Entity Address, State or Province |
CA
|
Entity Address, Postal Zip Code |
94022
|
City Area Code |
(650)
|
Local Phone Number |
284-4433
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
Stock, $0.0001 par value per share
|
Trading Symbol |
RNXT
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Grafico Azioni RenovoRx (NASDAQ:RNXT)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni RenovoRx (NASDAQ:RNXT)
Storico
Da Giu 2023 a Giu 2024